Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab

Intern Med. 2019 Jun 1;58(11):1573-1576. doi: 10.2169/internalmedicine.1791-18. Epub 2019 Feb 1.

Abstract

A 35-year-old man with refractory Crohn's disease showed a loss of response to infliximab after requiring treatment with infliximab at 10 mg/kg together with steroid to maintain remission. His symptoms recurred, and colonoscopy showed extensive active ulcers in the colon. Adrenomedullin therapy was started in addition to the conventional infliximab therapy. A few days after, his symptoms went into remission. Endoscopy at 2 and 7 weeks revealed significant mucosal remission without steroid therapy. Adrenomedullin promoted mucosal healing and led to the re-induction of remission in Crohn's disease in a patient with a loss of response to infliximab.

Keywords: Crohn's disease; adrenomedullin; inflammatory bowel disease; infliximab; loss of response; mucosal healing.

Publication types

  • Case Reports

MeSH terms

  • Adrenomedullin / therapeutic use*
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Crohn Disease / drug therapy*
  • Drug Therapy, Combination
  • Drug Tolerance
  • Gastrointestinal Agents / therapeutic use*
  • Glucocorticoids / therapeutic use
  • Humans
  • Infliximab / therapeutic use*
  • Male
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Glucocorticoids
  • Adrenomedullin
  • Infliximab